AzTrials
AzTrials

HealthyNCT01841255

UMOX™: A New Device for Preoxygenation

A study testing Mouthpiece (Umox) and facemask in people with Healthy, run by Maisonneuve-Rosemont Hospital at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background - Preoxygenation is performed before general anesthesia to increase the oxygen reserves of the body and prolong the safe period of apnea without hypoxia. However, it is often impossible to obtain a perfect face mask fit, and optimal end-tidal fractional oxygen concentration (EtO2) are not attained. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
Mouthpiece (Umox) and facemask
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
49 participants
Where
1 siteCanada
Study dates
Sep 2008to Nov 2008
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Both genders
  • smokers and non-smokers
  • American Society of Anesthesiologists (ASA) physical status I or II
  • 18 to 65 years old.

Who cannot join

  • Presence of any craniofacial abnormality
  • facial hair (beard or moustache) or absence of teeth.
  • Well-controlled non-severe asthma was not a criterion for exclusion.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Maisonneuve-Rosemont Hospital

    Montreal, Quebec, H1T 2M4

Other trials in Canada

About this study

Background - Preoxygenation is performed before general anesthesia to increase the oxygen reserves of the body and prolong the safe period of apnea without hypoxia. However, it is often impossible to obtain a perfect face mask fit, and optimal end-tidal fractional oxygen concentration (EtO2) are not attained. The investigators designed a new oropharyngeal preoxygenation device, UMOX™, to avoid leaks during preoxygenation. In this study, the investigators compared the efficacy of UMOX™ with that of a conventional face mask.

Methods - In 50 healthy volunteers breathing 100% oxygen from a circle absorber system for a 5 minute-period, the investigators compared preoxygenation using the 1) a conventional mask; 2) UMOX™ without any instruction; 3) UMOX™ with instruction on mouth breathing; and 4) UMOX™ with a nose clip, in random order. Each subject underwent all steps with a 10-minute rest period of room air breathing between each step. Inspired and end-tidal respiratory gases were measured every 10 seconds. EtO2 variation was analyzed using Anova.

Read the detailed description

This study was as a single center, crossover, randomized trial. Following approval from research and ethics committee from our hospital and written consent from healthy subjects recruited, 50 consenting volunteers were enrolled over a three-month period, from: September 29, 2008 to November 5, 2008.

Subjects enrolled were of both genders, smokers and non-smokers, American Society of Anesthesiologists (ASA) physical status I or II, 18 to 65 years old. Nonrecruitment depended on the presence of any craniofacial abnormality, facial hair (beard or moustache) or absence of teeth. Well-controlled non-severe asthma was not a criterion for exclusion.

The trial was conducted in an operating room, using the Dräger Fabius GS (Dräger, Canada), anesthesia machine in a usual set up with the operating table. The investigators used a, patient circuit system consists of 1.5-L lime soda absorber connected to disposable corrugated tubing and a 2-L breathing bag. Gases were analyzed through a Marquette Medical Systems™ SAM module (GE Healthcare), volumes monitored with a GE Respirator Mechanics-M (GE Healthcare) and SpO2 measured with a Nellcor™ (Covidien) pulse oximetry positioned on a finger. Preoxygenation procedures were explained to the subjects and ample time was allowed so they could become familiar with the mask and mouth piece. Set up for the measure was conducted by the same experimenter. Subjects laid supine and preoxygenation was performed with fresh gas flow: 100% oxygen (O2) 10L/minute, administered trough facemask or mouth piece sequentially in a random order. Randomization was established with a random assignment table (ww.randomization.com). The envelope was open as the subject entered the operating room (OR). At the beginning and between each step, the anesthesia circuit was flushed with 100% (O2). Each subject went through all steps in random order, each requiring a 5-min period of: 1) tidal breathing using the facemask (TVFM); 2) tidal volume breathing with the UMOXTM mouthpiece (TVMP); 3) tidal volume breathing with the UMOXTM mouthpiece and verbal instructions to favor mouth breathing (TVMPMB); (4) tidal volume breathing with the UMOXTM mouthpiece and a nose clip (TVMPNC). The experimenter conducting the steps instructed participants to create a seal with their lips around the mouthpiece and readjusted the facemask when the subject signalled a discernable leak. Each step was interrupted by 10 minutes of breathing normal room air to allow for return to original respiratory status. Continuous recording of experimental measures, displayed on the anesthesia monitoring system, was done on digital films (Canon PowershotS5 IS™). For the purpose of our trial, 10 seconds intervals were considered adequate for following preoxygenation trends. End-tidal O2 was measured continuously for 5 min. We have also evaluated the level of satisfaction of the subject with each technique using a 1-4 scale.Participants were asked to asses their comfort by showing the associated number with their fingers. Finally we described the performance of the facemask ventilation technique as reported by the experimenter on a scale of 1 to 4.Primary outcome was the end-tidal O2 at the end of the 5-minutes preoxygenation period. Secondary outcomes included endtidal O2 as a function of time, the number of subjects reaching at least 87% EtO2, subject satisfaction and ease of ventilation.

Based on the few studies available on different preoxygenation technques, the end-tidal oxygen fraction standard deviation can range from 5% to about 20% depending on the device used for preoxygenation3,4,14,15. Assuming a 12% value for standard deviation, sample size calculations were made for Type I and Type II errors of 5% and 20%, respectively (power of 80%). From these numbers and taking account that we would rely on multiple comparisons, the power analysis suggested that 50 subjects would allow us to find a difference between groups around 9%. The 9nvestigators analyzed the EtO2 final value with one-way ANOVA followed by the Tukey's Multiple Comparisons test. Percentage of participants reaching at least 87% EtO2 are described with survival curves compared with Kaplan-Meier log rank test. Tolerance is presented using Kruskal-Wallis with Dunn's Multiple Comparisons test.

Conditions
Healthy
Being tested
Mouthpiece (Umox), facemask
Keywords
Preoxygenation, Device, Tolerability, Efficacy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mouthpiece (Umox)Device

    Also called Umox

    Device used to perform preoxygenation in the operating room context

  • facemaskDevice

Study groups in NCT01841255
Study groupRoleWhat they receive
Tidal breathing using the facemaskSham comparatorControl
Receives: Device: facemask
Tidal volume breathing with the UMOXTM, device, no instructionExperimentalFirst experimental measure
Receives: Device: Mouthpiece (Umox)
Tidal volume breathing with the UMOXTM device, instructionsExperimentalSecond experimental measure
Receives: Device: Mouthpiece (Umox)
Tidal volume breathing with the UMOXTM, device, nose clipExperimentalThird experimental measure
Receives: Device: Mouthpiece (Umox)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary outcome measurement was the evolution of endtidal oxygen fraction during a 5 minute preoxygenation procedure, measurements were done continuously, maximum values were recorded

    The goal of this study is to compare the efficacy of preoxygenation using the conventional mask with the mouthpiece of the UMOX™ oropharyngeal device. The primary outcome measurement was endtidal oxygen fraction. The investigators also evaluated the respective tolerability of the two preoxygenation instruments in healthy volunteers. The measures were not part of a surgical procedure, participants were volunteers participating in this experimental design. No follow-up step was included in this protocol.

    Measured: The four steps were done sequentially, each step consisted of a 5 minute recording period under specific conditions, followed by a 10 minute pause before the next step

Secondary outcomes (1)
  1. The investigators also evaluated the respective tolerability of the two preoxygenation instruments in healthy volunteers with a short questionnaire

    Measured: The four steps were done sequentially, each step consisted of a 5 minute recording period under specific conditions, followed by a 10 minute pause before the next step

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Apr 2013 (estimated)
  2. Study startSep 2008
  3. Primary completionNov 2008
  4. Study completionNov 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
49 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01841255
Sponsor's protocol ID
06108
Status last verified
Jan 2013
First submitted
27 Feb 2013
Last updated
26 Apr 2013
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Mouthpiece (Umox) and facemask in people with Healthy, run by Maisonneuve-Rosemont Hospital at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Apr 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary outcome measurement was the evolution of endtidal oxygen fraction during a 5 minute preoxygenation procedure, measurements were done continuously, maximum values were recorded (time frame: The four steps were done sequentially, each step consisted of a 5 minute recording period under specific conditions, followed by a 10 minute pause before the next step). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Apr 2013.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in